WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that symptomatic and asymptomatic QTc prolongation, a measure of cardiac function, has been observed in a Phase 1 dose escalation trial with ARQ 171, a second generation product in its E2F-1 cancer therapy program
